Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07258446 · ClinicalTrials.gov registry record · NA

PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma

A NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8, sponsored by University of California, Davis.

Recruiting
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT07258446 is a NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 36 participants, below the 504-participant average among 4 other Clinical Stage I Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07258446, a NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage 0 to IIc cutaneous melanoma. SMMS is a method of skin cancer removal involving repeated tissue removal and examination under a microscope to ensure the tumor is removed as much as possible while sparing healthy tissue. In SMMS, tissue sections are evaluated to determine whether additional tissue removal is needed. The standard method for evaluating the tissue is by using a specific stain called hematoxylin and eosin (H\&E) stains. PRAME is a cancer antigen that is being investigated as a diagnostic marker in certain types of cancer. Adding PRAME IHC analysis to standard SMMS staining methods may improve the accuracy for determining whether additional tissue removal is necessary for patients undergoing SMMS for stage 0 to IIc cutaneous melanoma.

Interventions

  • DIAGNOSTIC_TEST Immunohistochemistry Staining Method
  • PROCEDURE Mohs Surgery

Study Locations (1)

California

  • University of California Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-10-24
Est. Completion 2033-11-01
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT07258446

The ClinicalTrials.gov registry entry for NCT07258446 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 504-participant average among 4 other Clinical Stage I Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (93% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Clinical Stage I Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Immunohistochemistry Staining Method is the first listed.

NCT07258446 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07258446 about?

NCT07258446 is a clinical study titled "PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma". This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage 0 to IIc cutaneous melanoma. SMMS is a method of skin cancer removal i...

What is the current status of trial NCT07258446?

This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2025-10-24. Estimated completion is 2033-11-01.

What conditions does trial NCT07258446 study?

This clinical trial studies the following conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage 0 Cutaneous Melanoma AJCC v8.

What interventions are being tested in trial NCT07258446?

The interventions under investigation include: Immunohistochemistry Staining Method (DIAGNOSTIC_TEST), Mohs Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT07258446?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07258446 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Clinical Stage I Cutaneous Melanoma AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.